Author

Shengyuan Zhang

Institution: University College London

Observed institutions: UCL School of Pharmacy, University College London

ORCID: 0009-0002-8741-8567

Observed ORCID: 0009-0002-8741-8567

OpenAlex ID: A5101950007

SARS‐CoV ‐2 viral dynamic modeling to inform model selection and timing and efficacy of antiviral therapy

2023 · Shengyuan Zhang, Akosua A. Agyeman, et al. · CPT Pharmacometrics & Systems Pharmacology · 15

Efficient in vitro assay for evaluating drug efficacy and synergy against emerging SARS-CoV-2 strains

2024 · Maximillian Woodall, Samuel Ellis, et al. · Antimicrobial Agents and Chemotherapy · 13

Molnupiravir clinical trial simulation suggests that polymerase chain reaction underestimates antiviral potency against SARS-CoV-2

2025 · Shadisadat Esmaeili, Katherine Owens, et al. · Journal of Clinical Investigation · 10

A Viroimmunologic Model to Characterize the Antiviral Effect of Molnupiravir in Outpatients Infected With SARS-CoV-2: Implication for Treatment Duration

2025 · Bach Tran Nguyen, Julie Bertrand, et al. · The Journal of Infectious Diseases · 4

Nirmatrelvir–ritonavir versus usual care in at-risk adults with early SARS-CoV-2 infection in the UK, 2022–23: virological and immunological results of an open-label randomised trial (PANORAMIC)

2026 · David M Lowe, Shengyuan Zhang, et al. · The Lancet Microbe · 3

Polymerase-inhibitor drug synergy and mutational signatures in different epithelial cell models of RSVA and hPIV3 infection

2026 · Samuel Ellis, Amy I. Jacobs, et al. · npj Antimicrobials and Resistance · 2

Works count: 6

Citation count: 47

H-index: 4

I10-index: 3